Arch Therapeutics Accepted to Present AC5® Advanced Wound System During Innovation Spotlight at 2022 Symposium on Advanced Wound Care (SAWC)
20 sept. 2022 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Launches Multi-Site Clinical Study for AC5® Advanced Wound System
07 sept. 2022 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Submits Application to Centers for Medicare and Medicaid Services for AC5® Advanced Wound System
01 sept. 2022 06h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Raises Approximately $3.5 Million in Convertible Note Financing
07 juil. 2022 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Provides Update on Reimbursement Strategy in Additional Selling Channel
22 juin 2022 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics’ Experts in Wound Care Interview Showcases AC5 Self-Assembling Peptide Technology During Live Session at SAWC Spring
09 mai 2022 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Renowned Wound Care Key Opinion Leaders Presented Arch Therapeutics’ AC5® Advanced Wound System at 2022 Symposium on Advanced Wound Care (SAWC) Spring
13 avr. 2022 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics’ AC5® Advanced Wound System to be Presented at 2022 Symposium on Advanced Wound Care (SAWC) Spring
04 avr. 2022 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Arch Therapeutics Partners with Centurion Therapeutics to Expand Access to AC5® Advanced Wound System
14 mars 2022 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...
Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities
06 janv. 2022 07h50 HE
|
Arch Therapeutics, Inc.
FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical...